BRASILIA (Reuters) - The Brazilian pharmaceutical company that plans to produce Russia’s coronavirus vaccine Sputnik V said on Tuesday it expects to overcome regulatory obstacles in “two or three” days to obtain authorization to make and sell the shot in Brazil.
Anvisa suspends mefenamic acid manufactured by National Pharmaceutical Chemistry Union SA